Curative Gene Therapy Coverage May Need Government-Funded Risk Pools

 
• By Cathy Kelly

Former US FDA commissioner Scott Gottlieb makes a case for regional or national risk pools to ensure pediatric patients get timely access to gene therapy like the upcoming treatments for sickle cell disease.

The little girl in the water park swimming underwater and smiling - Image
Disparity in access between Medicaid and private plans for high-cost therapies could be particularly problematic, Gottlieb says. • Source: Shutterstock

More from Pricing Debate

More from Market Access